Nabla Bio
YC S20 · Active · We use AI to design antibodies for intractable diseases
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCW18 | |
| AI | Active | YCS21 | |
| AI | Active | YCW20 | |
| AI | Active | YCW23 | |
| AI | Active | YCS21 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Not stated | Plug and Play | |
| AI | Active | YCS21 | |
| AI | Active | YCW20 | |
| AI | Active | YCS21 | |
| AI | Active | YCW22 |
Also from S20 in AI
All of S20About Nabla Bio
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
- YC batch
- S20 · Summer 2020
- Status, per YC
- Active
- Category
- AI
- Team size
- 8
- Location
- Boston, MA, USA
- Checked
- 35m ago
YC tags: AI-powered Drug Discovery
Nabla Bio: questions
Which YC batch was Nabla Bio in?
Nabla Bio was in Y Combinator's Summer 2020 batch (S20).
Is Nabla Bio still active?
Y Combinator lists Nabla Bio as active.
Where is Nabla Bio based?
Nabla Bio lists Boston, MA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.